Survival benefit of radiotherapy for metastatic nasopharyngeal carcinoma:a retrospective analysis based on SEER database
Li Xiangpan1, Zhang Huibo1, Yu Jianxiong2, Song Qibin1, Xiao Jianping3
1Department of Oncology,Renmin Hospital of Wuhan University,Wuhan 430060,China; 2Department of Gastrointestinal Surgery,Renmin Hospital of Wuhan University,Wuhan 430060,China; 3Department of Radiation Oncology, National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100021,China;
Abstract： Objective To analyze survival benefits of radiotherapy in patients with nasopharyngeal carcinoma (NPC) with distant metastases and analyze relevant prognostic factors. Methods Medical records of 329 patients newly diagnosed with metastatic NPC screened from the Surveillance, Epidemiology and End Results (SEER) database (199 of 329 patients received radiotherapy) between 2010 and 2015 were retrospectively analyzed. Overall survival (OS) and disease-specific survival (DSS) were calculated by Kaplan-Meier curve. The effect of different clinicopathological factors on the clinical prognosis of metastatic NPC patients was evaluated by logrank test and Cox regression analysis. Results The median follow-up time was 12 months. The 3-and 5-year OS rates were 27.4% and 19.7%. The median OS was 17.9 months. Univariate analysis demonstrated that patients aged< 50 years, male, undifferentiated type, stage T3 or T4, positive regional lymph node, brain and liver metastases and 1-2 metastatic sites obtained OS and DSS benefits at 3 years after radiotherapy. Univariate and multivariate Cox analyses after propensity score matching showed that radiotherapy was an independent prognostic factor for metastatic NPC (OS,P=0.004;DSS,P=0.014). Besides, patients aged 60-69 years (OS,P=0.033;DSS,P=0.045), keratinizing squamous cell carcinoma (OS,P<0.05;DSS,P<0.05), stage T4(OS,P=0.002;DSS,P=0.024),1-2 metastatic sites (OS,P=0.039;DSS,P=0.058),3-4 metastatic sites (OS,P=0.003;DSS,P=0.005) and no chemotherapy (OS,P=0.000;DSS,P=0.000) had poor OS and DSS, whereas sex, race and degree of differentiation exerted no effect on OS and DSS. Conclusions Radiotherapy can significantly improve the OS and DSS of patients with metastatic NPC. Prospective and randomized controlled studies are required to further explore the role of radiotherapy in the management of metastatic NPC.
Li Xiangpan,Zhang Huibo,Yu Jianxiong et al. Survival benefit of radiotherapy for metastatic nasopharyngeal carcinoma:a retrospective analysis based on SEER database[J]. Chinese Journal of Radiation Oncology, 2019, 28(1): 5-12.
[1] Chang ET,Adami HO.The enigmatic epidemiology of nasopharyngeal carcinoma[J].Cancer Epidemiol Biomark Prevent,2006,15(10):1765-1777.DOI:10.1158/1055-9965.EPI-06-0353. [2] Ferlay J,Soerjomataram I,Dikshit R,et al. Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):E359-E386.DOI:10.1002/ijc.29210. [3] Baujat B,Audry H,Bourhis J,et al. Chemotherapy in locally advanced nasopharyngeal carcinoma:An individual patient data meta-analysis of eight randomized trials and 1753 patients[J].Int J Radiat Oncol Biol Phys,2006,64(1):47-56. DOI:10.1016/j.ijrobp.2005.06.037. [4] Blanchard P,Lee A,Marguet S,et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma:an update of the MAC-NPC meta-analysis[J].Lancet Oncol,2015,16(6):645-655.DOI:10.1016/S1470-2045(15)70126-9. [5] Hu J,Kong L,Gao J,et al. Use of radiation therapy in metastatic nasopharyngeal cancer improves survival:a SEER analysis[J].Scic Rep,2017,7(1):721.DOI:10.1038/s41598-017-00655-1. [6] Prawira A,Oosting S F,Chen TW,et al. Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma:a systematic review[J].Br J Cancer,2017,117(12):1743-1752.DOI:10.1038/bjc.2017.357. [7] Wang CJ,Christie A,Lin M,et al. Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases[J].Int J Radiat Oncol Biol Phys,2017,98(1):91-100.DOI:10.1016/j.ijrobp.2017.01.032. [8] Zhu H,Zhou Z,Wang Y,et al. Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis[J].Cancer,2011,117(23):5423-5431.DOI:10.1002/cncr.26206. [9] Zhang C,Pan Y,Zhang Q,et al. The influence of local therapy on the survival of patients with metastatic rectal cancer:a population-based,propensity-matched study[J].J Cancer Res Clin Oncol,2017,143(9):1891-1903.DOI:10.1007/s00432-017-2442-2. [10] Lin S,Tham IWK,Pan J,et al. Combined high-dose radiation therapy and systemic chemotherapy improves survival in patients with newly diagnosed metastatic nasopharyngeal cancer[J].Am J Clin Oncol,2012,35(5):474-479.DOI:10.1097/COC.0b013e31821a9452. [11] Majewski W,Tabor M,Banaszek P,et al. The efficacy of stereotactic radiotherapy for metastases from renal cell carcinoma[J].Neoplasma,2016,63(1):99-106.DOI:10.4149/neo_2016_012. [12] Aoyama H,Tago M,Shirato H.Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases:secondary analysis of the JROSG 99-1 randomized clinical trial[J].JAMA Oncol,2015,1(4):457-464.DOI:10.1001/jamaoncol.2015.1145. [13] Sperduto PW,Shanley R,Luo X,et al. Secondary analysis of RTOG 9508,a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases;poststratified by the graded prognostic assessment (GPA)[J].Int J Radiat Oncol Biol Phys,2014,90(3):526-531.DOI:10.1016/j.ijrobp.2014.07.002. [14] Lorimore SA,Chrystal JA,Robinson JI,et al. Chromosomal instability in unirradiated hemaopoietic cells induced by macrophages exposed in vivo to ionizing radiation[J].Cancer Res,2008,68(19):8122-8126.DOI:10.1158/0008-5472.CAN-08-0698. [15] Golden EB,Chhabra A,Chachoua A,et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours:a proof-of-principle trial[J].Lancet Oncol,2015,16(7):795-803.DOI:10.1016/S1470-2045(15)00054-6. [16] Yeh S,Tang Y,Lui C,et al. Treatment Outcomes of patients with AJCC stage ⅣC nasopharyngeal carcinoma:benefits of primary radiotherapy[J].Japa J Clin Oncol,2006,36(3):132-136.DOI:10.1093/jjco/hyi245. [17] Li J,Huang S,Wen B,et al. Prognostic factors on overall survival of newly diagnosed metastatic nasopharyngeal carcinoma[J].Asian Paci J Cancer Prevent,2014,15(7):3169-3173.DOI:org/10.7314/APJCP.2014.15.7.3169. [18] Chen M,Jiang R,Guo L,et al. Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis[J].Chin J Cancer,2013,32(11):604-613.DOI:10.5732/cjc.013.10148. [19] Lai S,Li W,Chen L,et al. How does intensity-modulated Rradiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?[J].Int J Radiat Oncol Biol Phys,2011,80(3):661-668.DOI:10.1016/j.ijrobp.2010.03.024. [20] Peng G,Wang T,Yang K,et al. A prospective,randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs.conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma[J].Radiother Oncol,2012,104(3):286-293.DOI:10.1016/j.radonc.2012.08.013. [21] Nutting CM,Morden JP,Harrington KJ,et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT):a phase 3 multicentre randomised controlled trial[J].Lancet Oncol,2011,12(2):127-136.DOI:10.1016/S1470-2045(10)70290-4.
2019, Vol. 28 
